OpenDNA

An AI platform combining clinical and genomic data analysis for polygenic diseases.

Health Tech & Life Sciences
Active
Seed Haifa, Israel Founded 2018
Last updated 2026-07-20
Total raised
$5.3M
Last: Grant 2023-10
Stage
Seed
Founded
2018
Headcount
4
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

OpenDNA is developing an AI platform that combines clinical and genomic data analysis for polygenic diseases. The platform allows healthcare providers and payers to easily apply genomic precision medicine and population genomics approaches. Its prediction models help identify high-risk patients and their key prevention strategies. The company has already implemented its AI solutions for cardiometabolic syndrome and plans to apply the technology to other complex polygenic disease states, such as cancer, chronic kidney failure, and autoimmune, neurological, and musculoskeletal diseases. OpenDNA continues to lead in the integration of genomics, polygenic risk scoring, and artificial intelligence to predict and prevent chronic diseases—including cardiometabolic conditions, cancer, autoimmune, neurological, and ocular diseases. Their SaaS platform seamlessly connects with leading EMRs such as AthenaHealth, delivering AI-powered healthcare management plans that support clinicians in identifying and managing high-risk patients through advanced genetic and clinical data analysis.

Funding history · 6 rounds · $5.3M total

2024-11
C Round $3.6M
★ PipelBiz
2023-09
Grant $250K
2023-02
Grant $500K
2023-02
B Round $1.0M
2022-02
A Round Undisclosed
★ ExitValley
2020-05
Seed Undisclosed
★ MindUP★ Israel Innovation Authority

Headcount over time

From 4 (2021-12) to 7 (2025-10) · +3 (+75%) · 7 points · source: Finder history + radar grounding
80 2021-12 2025-10

Q&A

What is OpenDNA's primary focus?
OpenDNA is developing an AI platform that combines clinical and genomic data analysis for polygenic diseases, with an initial focus on predicting and preventing heart disease.
When was OpenDNA founded?
OpenDNA was founded in September 2018.
What is OpenDNA's total funding to date?
OpenDNA has raised a total of $2,450,000 USD.
When was OpenDNA's most recent funding round?
OpenDNA's most recent funding round was a Grant in October 2023, raising $250,000 USD.
Which investors participated in OpenDNA's June 2020 funding round?
MindUP and Israel Innovation Authority participated in OpenDNA's June 2020 funding round.
What is OpenDNA's current product stage?
OpenDNA's product is currently in the clinical trial stage.
Who are the founders of OpenDNA?
The founders of OpenDNA are Eran Feldhay, who serves as Founder & CEO, and Erez Ornan, who is the VP R&D.

Team · 1

Eran Feldhay
Founder · Founder & CEO

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Technologies
BiologicalsGenesArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcareProvidersInsurance Companies
Business model
B2B

Highlights

1 PatentsVerified

Tags

blood-pressurechronic-diseasehealthcare-providerscardiovasculardigital-healthcareartificial-intelligencepatientsheart-diseasespersonalized-medicinemhealthdiabetesgeneticsheart-failure
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteopen-dna.com
LinkedInlinkedin.com/company/75003430

Identifiers & details

Founded2018-9
Employees (exact)4

Radar intelligence

Patents

EPO4

Publications (Crossref)

Works2

GitHub

Top reposredmine, ey-cloud-recipes, scoreranking-api, bootstrap

Web history (Wayback)

Domainopen-dna.com

Certificate / subdomain footprint

Subdomains1

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)515903276
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2018-09-16
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)yes
Last annual report2023
Active charges / liens0
Registry events2 — violation (1), shares_capital (1)
Registered addressנתיב האור 1 חיפה

Recent registry events

DateEvent
2026-06-25עדכון הפרה
2026-06-25הקצאת מניות